Colo-rectal cancer Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Pharmacy inclusion criteria: 1. South Yorkshire pharmacies in LSOAs in Deciles 1 and 2 of the Index of Multiple Deprivation. 2. Willing to be randomised to active case finding or usual care. 3. Willing to distribute FIT kits to people attending pharmacy as per the details in protocol. 4. Have read the study-specific SOP and can follow all the elements laid out therein. 5. Have access to PharmOutcomes online system. 6. Have completed the required ACF training associated with the service. 7. Able to offer face to face consultations in a private room.
Exclusion criteria
Exclusion criteria: Pharmacy exclusion criteria: 1. Unable to meet the trial requirements for storing and distributing FIT kits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of recruitment to main trial: Number of people who were given a FIT kit from pharmacies delivering the active case finding service (measured using screening log data collected by participating pharmacies) over 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Intervention adherence - defined objectively as the number of FIT samples performed after dissemination in pharmacy settings - (measured using a unique identifier to enable tracking when the test is received by the central lab) over 12 months. 2. Patients’ views on acceptability of research procedures and intervention measured using semi structured qualitative interviews after at least 3 months of ACF service being delivered. 3. Pharmacists’ views on intervention/research protocol acceptability measured using semi structured qualitative interviews after at least 3 months of ACF service being delivered. 4. General Practitioners’ views on intervention/research protocol acceptability measured using semi structured qualitative interviews after at least 3 months of ACF service being delivered. 5. Feasibility of recruiting community pharmacies - measured using field notes to record problems with project approvals and set-up at participating pharmacy sites; target sites for the main trial. | — |
Countries
England, United Kingdom